Vanguard Group’s Aptevo Therapeutics APVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $159K | Buy |
+16,856
| New | +$401K | ﹤0.01% | 4134 |
|
|
2024
Q1 | – | Hold |
0
| – | -$16.6K | – | 4451 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 4458 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 4375 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 4219 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 4139 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 4070 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 4095 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 4139 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 4095 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 4090 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 4046 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 3833 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 3641 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 3318 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 3791 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 3768 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 3844 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 3771 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 3815 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 3679 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 3552 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 3587 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 3332 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 3313 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 3393 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 3289 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 3468 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 3477 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3459 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3350 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3365 |
|
Other funds holding APVO
Vanguard Group's APVO Position: Q4 2025 in Review
Vanguard Group opened a new position in Aptevo Therapeutics (APVO) in Q4 2025: 16,856 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #4134 among its holdings.
11 funds tracked by Wall St. Rank hold APVO as of Q4 2025.
- Vanguard Group held 16,856 shares of Aptevo Therapeutics worth $159K as of Q4 2025.
- Aptevo Therapeutics was a new Vanguard Group position in Q4 2025.
- Aptevo Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4134 holding.
- 11 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.